Device / Technology News

RSS

Researchers develop series of techniques to create active iron-based catalysts

University of Toronto researchers have developed a series of techniques to create a variety of very active iron-based catalysts necessary to produce the alcohols and amines used in the drug and perfume industry. The new synthetic methods promise to be safer and more economical and environmentally friendly than traditional industrial processes.

30 Nov 2013

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing assays, assisting researchers to make informed decisions when designing studies.

From Oxford Gene Technology 30 Nov 2013

CoActiv Medical to introduce EXAM-PACS version 3.0 at 2013 RSNA conference

CoActiv Medical debuts at the 2013 Radiological Society of North America conference EXAM-PACS version 3.0. CoActiv leverages its longstanding experience with standards-based technology to bring new market-leading features and functionality to its flagship enterprise PACS and to provide more options and flexibility across the entire product line with expanded deployment options and a more robust vendor neutral archive.

29 Nov 2013

Sumitomo receives FDA 510(k) clearance for Proton Therapy System

Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.

29 Nov 2013

World's first clinical trial to use MLC tracking system to improve prostate cancer radiotherapy treatment

Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.

28 Nov 2013

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.

28 Nov 2013

Smartphone-based imaging could help physicians in remote locations to monitor patients' health

The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series features an advance in smartphone-based imaging that could help physicians in resource-limited locations monitor their patients' health.

28 Nov 2013

Miller Reese Hutchinson patents first portable electric hearing aid

This month in 1901 brought good news for the hard of hearing, as Miller Reese Hutchinson of New York patented the first portable electric hearing aid. Called the "acousticon," the device was a smaller version of previous tabletop units.

28 Nov 2013

Screening for genetic mutations may help identify silent carriers of adrenal Cushing's syndrome

Genetic research that will be published tomorrow in the New England Journal of Medicine suggests to Dr. André Lacroix, professor at the University of Montreal, that clinicians' understanding and treatment of a form of Cushing's syndrome affecting both adrenal glands will be fundamentally changed, and that moreover, it might be appropriate to begin screening for the genetic mutations that cause this form of the disease.

28 Nov 2013

Leti highlights new imaging technology at IEEE Nuclear Science Symposium & Medical Imaging Conference

Researchers from CEA-Leti’s Detector Laboratory presented four oral papers and one invited paper at the recent IEEE Nuclear Science Symposium & Medical Imaging Conference & Workshop on Room-Temperature Semiconductor X-Ray and Gamma-Ray Detectors in Seoul, Korea.

28 Nov 2013

Researchers create breathalyzer that may help control blood sugar

Finger pricks may soon be a thing of the past for diabetics. Researchers at Western New England University have created a breathalyzer that may help control blood sugar by measuring the amount of acetone in the breath.

27 Nov 2013

Current laser therapy approaches provide effective treatment for excessive scars

Current laser therapy approaches are effective for treating excessive scars resulting from abnormal wound healing, concludes a special topic paper in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

27 Nov 2013

Penn Medicine incorporates automated prediction tool that aims to reduce hospital readmissions

An automated prediction tool which identifies newly admitted patients who are at risk for readmission within 30 days of discharge has been successfully incorporated into the electronic health record of the University of Pennsylvania Health System. The tool, developed by researchers at the Perelman School of Medicine, is the subject of a study published in the December issue of the Journal of Hospital Medicine.

27 Nov 2013

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

In March 2013, Eric Wagner told his wife to call 9-1-1 because he was feeling the worst that he had ever felt. He was rushed by EMS to University Hospitals (UH) Ahuja Medical Center, and then airlifted to UH Case Medical Center, where brain scans showed that he had a ruptured aneurysm, a leaking blister on a blood vessel that was letting blood flow into his brain and causing a stroke.

27 Nov 2013

Bioaxial secures funds to market optical microscopy modules

Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.

27 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

FDA grants Orphan Drug Designation to CMC Contrast's CMC-001 MRI contrast media

CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001.

27 Nov 2013

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013

Researchers develop prototype spacesuit biosensors to monitor astronauts' health

Kansas State University researchers are improving astronauts' outerwear for outer space. The collaborative team -- which includes electrical and computer engineering professors and more than a dozen students -- envisions a future spacesuit that could monitor astronauts' health and use body heat to power electronics.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Device / Technology News

Researchers develop series of techniques to create active iron-based catalysts

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

CoActiv Medical to introduce EXAM-PACS version 3.0 at 2013 RSNA conference

Sumitomo receives FDA 510(k) clearance for Proton Therapy System

World's first clinical trial to use MLC tracking system to improve prostate cancer radiotherapy treatment

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

Smartphone-based imaging could help physicians in remote locations to monitor patients' health

Miller Reese Hutchinson patents first portable electric hearing aid

Screening for genetic mutations may help identify silent carriers of adrenal Cushing's syndrome

Leti highlights new imaging technology at IEEE Nuclear Science Symposium & Medical Imaging Conference

Researchers create breathalyzer that may help control blood sugar

Current laser therapy approaches provide effective treatment for excessive scars

Penn Medicine incorporates automated prediction tool that aims to reduce hospital readmissions

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

Bioaxial secures funds to market optical microscopy modules

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

FDA grants Orphan Drug Designation to CMC Contrast's CMC-001 MRI contrast media

Fluxion Biosciences reports first study results from early stage NSCLC patients

Researchers develop prototype spacesuit biosensors to monitor astronauts' health

UMass Medical School licenses "anti-gal" technology to Agalimmune

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News